Technical Analysis for EBS - Emergent Biosolutions, Inc.

Grade Last Price % Change Price Change
F 77.64 4.26% 3.17
EBS closed up 4.26 percent on Friday, April 16, 2021, on 73 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Apr 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical EBS trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 4.26%
NR7 Range Contraction 4.26%
Inside Day Range Contraction 4.26%
Wide Bands Range Expansion 4.26%
Oversold Stochastic Weakness 4.26%
Slingshot Bearish Bearish Swing Setup 4.26%
Older End-of-Day Signals for EBS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Emergent Biosolutions, Inc. Description

Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Solid Tumors Drugs IBD 50 Monoclonal Antibody Influenza Rheumatoid Arthritis FDA Vaccine Vaccination Inflammatory Bowel Disease Lotion Blood Plasma Chronic Lymphocytic Leukemia Lymphocytic Leukemia Decontamination Specialized Products Biodefense Biological Warfare Host Disease Graft Versus Host Disease Anthrax Chemical Warfare Chemical Warfare Agents Anthrax Vaccines

Is EBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 137.61
52 Week Low 66.01
Average Volume 659,253
200-Day Moving Average 99.35
50-Day Moving Average 95.34
20-Day Moving Average 84.14
10-Day Moving Average 76.79
Average True Range 3.92
ADX 31.27
+DI 16.69
-DI 34.13
Chandelier Exit (Long, 3 ATRs ) 84.28
Chandelier Exit (Short, 3 ATRs ) 83.30
Upper Bollinger Band 100.17
Lower Bollinger Band 68.11
Percent B (%b) 0.3
BandWidth 38.11
MACD Line -5.56
MACD Signal Line -5.19
MACD Histogram -0.3677
Fundamentals Value
Market Cap 4.11 Billion
Num Shares 53 Million
EPS 3.11
Price-to-Earnings (P/E) Ratio 24.94
Price-to-Sales 3.30
Price-to-Book 3.49
PEG Ratio 1.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.71
Resistance 3 (R3) 82.20 80.00 81.87
Resistance 2 (R2) 80.00 78.71 80.26 81.58
Resistance 1 (R1) 78.82 77.91 79.41 79.33 81.30
Pivot Point 76.62 76.62 76.92 76.88 76.62
Support 1 (S1) 75.44 75.33 76.03 75.95 73.98
Support 2 (S2) 73.24 74.53 73.50 73.70
Support 3 (S3) 72.06 73.24 73.42
Support 4 (S4) 72.57